The Prohibition Model: North Carolina Bans Litigation Funding

The Prohibition Model: North Carolina Bans Litigation Funding

On June 22, 2026, North Carolina became the first US state to ban third-party litigation funding outright — not disclosure, not a cap, a flat prohibition. Here’s what the statute actually does, and what it means for the asset class.

My angle here isn’t a lawyer’s — it’s an investor’s. I have real money in litigation finance: a legacy retail book of individual funded cases that’s now winding down, and — where I put new capital — commitments to private litigation finance funds. So I don’t read a state outlawing the practice as an abstract policy fight. I read it as a question about whether the legal ground under an entire asset class is shifting — and whether I’m being paid enough to keep standing on it.

The Headline

Most states fighting over litigation finance have landed on disclosure — make funders register, reveal the agreement, bar them from controlling strategy. Kansas, Michigan, and others passed versions of that this year. North Carolina just did something categorically different: it banned the practice.

Governor Josh Stein signed House Bill 315 — the Prohibit Litigation Investments Act — into law on June 22, 2026 (Session Law 2026-14), effective immediately. It passed the House unanimously and cleared the Senate 45-1. The bill was championed by the North Carolina Chamber and backed by the U.S. Chamber’s Institute for Legal Reform.

Statute HB 315 / SL 2026-14 (GS Ch. 66, Art. 52)
Signed June 22, 2026 (effective immediately)
Model Prohibition — not disclosure
House vote Unanimous
Senate vote 45-1
Civil penalty Up to $50,000 per violation (AG-enforced)
Private remedy Treble the contemplated investment

What the Statute Actually Does

The operative language (GS 66-514) makes it unlawful to “engage in litigation investment in this State or to furnish litigation investment to a party or counsel of record in a civil proceeding in this State.” “Litigation investment” is defined as providing money for the fees, costs, or expenses of a pending or potential civil proceeding in return for compensation contingent on the outcome.

Two things matter about that trigger:

  1. The hook is the North Carolina proceeding — not where the funder is located. A New York or London funder backing an NC-venued case is in scope.
  2. It reaches both the party and “counsel of record.” That sweeps in portfolio facilities extended to law firms, not just single-case deals with a plaintiff.

The Teeth

This isn’t a registration form with a late fee. The enforcement structure is aggressive:

Mechanism Effect
Contract voided (GS 66-515) The offending funding agreement is unenforceable
AG civil penalty Up to $50,000 per violation; AG may seek injunctions
Private right of action Injured parties recover statutory damages of treble the contemplated investment
Long-arm jurisdiction Funder is “purposefully availed” and subject to suit in NC “whether they have transacted business in the State or not”

That last row is the one funders should reread. The statute reaches out and asserts personal jurisdiction over an out-of-state funder solely because it financed an NC case — and instructs courts to construe the Act liberally to effect its purpose.

The Carve-Outs Don’t Help Commercial Funders

The Act exempts a few things, but none of them shelter the commercial model:

  • Pro bono and nonprofit legal aid funding
  • An insurer’s defense or indemnification obligations
  • Loans or financial support not contingent on the outcome of the proceeding

Outcome-contingent return is the entire commercial funding model. A non-recourse advance that gets repaid only on a win — whether it’s a single commercial case or a portfolio facility — is exactly what the statute prohibits. The carve-outs describe everything litigation finance isn’t.

Who Is Actually Affected?

Here’s the nuance the headlines miss: the direct, near-term hit to most large commercial funders is probably modest.

The high-value commercial disputes that anchor a serious funder’s book — antitrust, patent, breach of contract, international arbitration — venue overwhelmingly in Delaware, the Southern District of New York, the big federal dockets, and arbitral seats. North Carolina state court is not where this capital concentrates. So NC-specific deal flow is a small slice of a typical commercial portfolio, and the number of contracts directly voided on day one is likely small.

That’s the reassuring read. The exposure that actually bites is more subtle:

Exposure vector Why it matters
Active / pipeline NC-venued matters Any agreement financing an NC case is now at risk of being unenforceable
Portfolio facilities that touch NC cases The “counsel of record” language can reach a multi-case facility even if the funder never set foot in NC; expect explicit NC carve-outs in new facilities
Consumer / pre-settlement funders More NC retail exposure than commercial funders, and no transparency-regime middle ground to fall back on
The precedent This is a template other states can copy — the real risk

The Real Story Is Precedent Risk

The reason this matters beyond North Carolina is that it breaks the pattern. Every other state that “regulated” litigation finance this cycle picked the disclosure lane — annoying for funders, but survivable, and arguably even helpful for legitimizing the asset class. North Carolina picked prohibition, and it did so with a near-unanimous, bipartisan vote and a well-funded Chamber coalition behind it.

That combination — a clean legislative template plus a demonstrated path to passage — is what makes copycats plausible. Industry coverage was blunt about it: the question isn’t whether NC’s own ban reshapes the market (it won’t, on its own), it’s whether a handful of states follow. If three or four states adopt prohibition models, that’s a structural repricing of the asset class — venue risk becomes a first-order underwriting input, not a footnote.

I want to be careful not to overstate it, though. Model legislation gets introduced far more often than it gets enacted, and the dominant trend this cycle is still disclosure, not prohibition — most legislatures that touched the issue chose the survivable lane. So the honest base case is that North Carolina stays an outlier, or close to it; prohibition cascading across several states is a tail scenario, not the modal one. But it’s a tail worth pricing, because the payoff is asymmetric: a disclosure regime I can underwrite around, whereas a spreading prohibition movement quietly raises the floor on risk for the entire asset class. Low-ish probability, high impact, hard to hedge — exactly the kind of risk that’s easy to wave away right up until it isn’t.

Three Open Questions That Set the Magnitude

How much this actually costs the industry depends on questions the statute doesn’t cleanly answer — and that will get litigated:

Question Why it’s unresolved
Retroactivity Does “voids any contract in violation” reach pre-existing agreements on in-flight NC cases, or only new ones? Retroactive voiding invites Contracts Clause and due-process challenges.
Federal reach Can a state statute govern funding of cases in NC federal courts? There’s a credible Erie / preemption argument that it can’t fully — which would leave a federal-diversity lane partly open.
Constitutionality The aggressive long-arm provision raises dormant-Commerce-Clause and extraterritoriality concerns. Expect the funding industry to look for a test case.

What This Means for Retail-Adjacent Litigation Finance

I spent years on the retail end of litigation finance — the crowdfunding platforms that let individuals buy slices of funded cases. That door has effectively closed: LexShares, the platform that pioneered it, is in harvest mode with no scaled successor, so retail access to the asset class now runs almost entirely through funds (or buying a public funder’s stock outright). I stopped backing new single cases after 2020; any new capital now goes to funds. So the real question isn’t whether a venue ban hits a retail case-picker — that channel barely exists anymore — it’s whether it reaches the funds that are now the only practical door.

Indirectly, yes — through two channels:

  1. Fund deal supply. A prohibition trend that pushes funders to screen out entire states shrinks the opportunity set even disciplined funds can underwrite. Since funds are now retail’s main door into litigation finance, a smaller, more constrained pipeline eventually shows up in the net returns those funds deliver.
  2. The regulatory signal. Prohibition (vs. disclosure) reflects a political judgment that the activity itself is illegitimate, not just opaque. That framing — “litigation as a market for financial investment” is something to stop — is the kind of narrative that, if it spreads, raises the tail risk on every litigation finance position, retail or institutional — the funds I hold today included.

None of this changes the core lesson I keep relearning: in litigation finance, the structural and procedural risks — standing, collectability, enforcement, and now venue legality — routinely matter more than the merits of the underlying claim. North Carolina just added a new line item to that list.

Where I Land

  1. The direct impact is small; the precedent is the point. NC isn’t a core venue for commercial funding, so the day-one balance-sheet hit is limited. The thing to watch is the copycat count.
  2. Prohibition is a worse outcome for the industry than disclosure. Disclosure regimes, however irritating, implicitly accept the asset class. A ban says the activity shouldn’t exist. That’s a more dangerous template precisely because it’s cleaner to copy.
  3. Venue is now an underwriting input. Expect funding agreements and portfolio facilities to start carving out prohibition states explicitly, and expect a constitutional test case before long.

For now, North Carolina stands alone, and I’m not about to unwind a litigation finance allocation over one state I have no active exposure in. What I am doing is adding “regulatory and venue regime” to the short list of questions I ask before committing to a fund — right next to the underwriting quality, the fee stack, and the liquidity terms I already learned to interrogate the hard way. The question the whole industry is sitting with is whether “first” turns out to mean “only,” or “first of many.” I’m underwriting for the second while hoping for the first.

Update — July 2026: The First Hard Data That Disclosure Moves Cases

A few weeks on, a data point landed that sharpens the argument above. Fresh analysis (via MLex) of a University of Utah study by Prof. Jonas Anderson tracked what happened after Delaware’s federal court began forcing funder disclosure — Chief Judge Colm Connolly’s April 2022 standing order requiring parties to name their funders and state whether the funder controls litigation or settlement. In the two years that followed, patent filings in Delaware fell 41% (1,899 → 1,121) against a national decline of just 15%; by 2024, only one funded patent case was filed in Connolly’s courtroom. The cases didn’t vanish — they migrated to Texas and other districts that keep funding confidential.

That complicates the tidy line I drew above between “survivable disclosure” and “dangerous prohibition.” Disclosure is still the milder regime — it accepts the asset class rather than outlawing it — but it is plainly not costless. A pure transparency rule, with no ban attached, already relocated roughly two-fifths of the affected patent docket. It’s the cleanest evidence yet for the point I keep landing on: venue and regulatory regime are first-order underwriting inputs, not footnotes. If mere disclosure moves that many cases, a spreading prohibition wave wouldn’t just reprice the asset class — it would redraw the map of where funded litigation can be brought at all.

Sources

Commentary and personal experience — not investment, legal, or tax advice. Investing carries risk, including total loss of capital. Always do your own due diligence.